• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃及弥漫性大 B 细胞淋巴瘤患者中 MYD88 L265P 和 TNFAIP3 突变的流行率及其与临床血液学特征的相关性。

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.

机构信息

Hematology Unit, Department of Clinical Pathology, Mansoura Faculty of Medicine, Mansoura University, Egypt.

Medical Oncology Unit, Department of Internal Medicine, Oncology Center, Faculty of Medicine, Mansoura University, Egypt.

出版信息

Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2485-2491. doi: 10.31557/APJCP.2023.24.7.2485.

DOI:10.31557/APJCP.2023.24.7.2485
PMID:37505783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10676502/
Abstract

BACKGROUND

Activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic active B-cell receptor signaling and a constitutive activation of the NF-KB pathway. MYD88 L265P mutation occurs as a driving force of NF-KB overactivity in ABC-DLBCL. Nonetheless, in cases of DLBCL, the MYD88 L265P mutation has not yet been investigated in association with the tumour necrosis factor alpha induced protein3 (TNFAIP3) mutation.

OBJECTIVE

To investigate the frequency of MYD88 and TNFAIP3 mutations in DLBCL and their association to the clinico-hematological profile.

MATERIAL AND METHODS

We used real-time polymerase chain reaction in order to search for MYD88 L265P and TNFAIP3 mutations in 100 DLBCL patients.

RESULTS

MYD88 L265P In 20% of cases, the CT heterozygous genotype was discovered.  CT heterozygous genotype was more common in ABC type, stage IV, greater IPI groups, extra-nodal infiltration, and BM infiltration. It was also linked to a shorter OS. TNFAIP3 mutation GA heterozygous genotype was detected in 18% of the patients, with ABC-DLBCL subtype accounting for 77.8%. The GA heterozygous genotype was usually related with stage IV, extranodal infiltration, and a reduced life expectancy.

CONCLUSION

MYD88 L265P and to lesser extent TNFAIP3 mutations are major mutations in ABC- DLBCL and may be predictive factors for poor OS in ABC- DLBCL patients.

摘要

背景

激活 B 细胞样(ABC)亚型弥漫性大 B 细胞淋巴瘤(DLBCL)的特征是慢性活跃的 B 细胞受体信号和 NF-KB 通路的组成性激活。MYD88 L265P 突变是 ABC-DLBCL 中 NF-KB 过度活跃的驱动因素。尽管如此,在 DLBCL 病例中,MYD88 L265P 突变与肿瘤坏死因子α诱导蛋白 3(TNFAIP3)突变之间的关联尚未得到研究。

目的

研究 MYD88 和 TNFAIP3 突变在 DLBCL 中的频率及其与临床血液学特征的关联。

材料和方法

我们使用实时聚合酶链反应来搜索 100 例 DLBCL 患者中的 MYD88 L265P 和 TNFAIP3 突变。

结果

MYD88 L265P 在 20%的病例中发现了 CT 杂合基因型。CT 杂合基因型在 ABC 型、IV 期、较高的 IPI 组、结外浸润和 BM 浸润中更为常见。它还与较短的 OS 相关。TNFAIP3 突变 GA 杂合基因型在 18%的患者中检测到,其中 ABC-DLBCL 亚型占 77.8%。GA 杂合基因型通常与 IV 期、结外浸润和预期寿命缩短有关。

结论

MYD88 L265P 和在较小程度上 TNFAIP3 突变是 ABC-DLBCL 的主要突变,可能是 ABC-DLBCL 患者 OS 不良的预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5b/10676502/b1babce3cc06/APJCP-24-2485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5b/10676502/b1babce3cc06/APJCP-24-2485-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5b/10676502/b1babce3cc06/APJCP-24-2485-g001.jpg

相似文献

1
The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.埃及弥漫性大 B 细胞淋巴瘤患者中 MYD88 L265P 和 TNFAIP3 突变的流行率及其与临床血液学特征的相关性。
Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2485-2491. doi: 10.31557/APJCP.2023.24.7.2485.
2
Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.原发性乳腺弥漫性大B细胞淋巴瘤中频繁出现的MYD88 L265P和CD79B突变
Am J Surg Pathol. 2016 Mar;40(3):324-34. doi: 10.1097/PAS.0000000000000592.
3
MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤中 MYD88 的表达和 L265P 突变。
Hum Pathol. 2013 Jul;44(7):1375-81. doi: 10.1016/j.humpath.2012.10.026. Epub 2013 Feb 4.
4
Overexpression Inhibits Diffuse Large B-Cell Lymphoma Progression by Promoting Autophagy through TLR4/MyD88/NF-κB Signaling Pathway.过表达通过 TLR4/MyD88/NF-κB 信号通路促进自噬来抑制弥漫性大 B 细胞淋巴瘤的进展。
Discov Med. 2024 Aug;36(187):1627-1640. doi: 10.24976/Discov.Med.202436187.149.
5
Oncogenically active MYD88 mutations in human lymphoma.人类淋巴瘤中致癌性激活的 MYD88 突变。
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
6
Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.MYD88 L265P 突变与非 L265P 突变弥漫性大 B 细胞淋巴瘤相关基因组改变的生物学和临床意义:361 例分析。
Clin Cancer Res. 2017 May 1;23(9):2232-2244. doi: 10.1158/1078-0432.CCR-16-1922. Epub 2016 Dec 6.
7
HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.HSP110 通过稳定 MyD88 维持激活 B 细胞弥漫大 B 细胞淋巴瘤中的慢性 NF-κB 信号传导。
Blood. 2018 Aug 2;132(5):510-520. doi: 10.1182/blood-2017-12-819706. Epub 2018 Jun 5.
8
Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients.临床、实验室和淋巴结 MYD88 L265P 突变在弥漫性大 B 细胞淋巴瘤患者风险评估中的作用。
J Egypt Natl Canc Inst. 2024 Oct 14;36(1):31. doi: 10.1186/s43046-024-00237-z.
9
MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.MYD88 L265P 突变,但无其他变异,可鉴定生发中心 B 细胞来源、结外累及、预后不良的 DLBCL 患者亚群。
Clin Cancer Res. 2016 Jun 1;22(11):2755-64. doi: 10.1158/1078-0432.CCR-15-1525. Epub 2016 Jan 20.
10
Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.49例原发性胃肠道弥漫性大B细胞淋巴瘤的临床病理特征;与发病部位、起源细胞及MYD88 L265P频率的比较
Pathol Int. 2016 Aug;66(8):444-52. doi: 10.1111/pin.12439. Epub 2016 Jul 20.

引用本文的文献

1
Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.描绘墨西哥患者前瞻性队列中弥漫性大 B 细胞淋巴瘤的突变特征。
Int J Mol Sci. 2024 Aug 28;25(17):9328. doi: 10.3390/ijms25179328.

本文引用的文献

1
NF-κB Mutations in Germinal Center B-Cell Lymphomas: Relation to NF-κB Function in Normal B Cells.生发中心B细胞淋巴瘤中的NF-κB突变:与正常B细胞中NF-κB功能的关系
Biomedicines. 2022 Oct 1;10(10):2450. doi: 10.3390/biomedicines10102450.
2
Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.弥漫性大 B 细胞淋巴瘤中体细胞突变的预后和治疗价值:系统评价。
Crit Rev Oncol Hematol. 2021 Sep;165:103430. doi: 10.1016/j.critrevonc.2021.103430. Epub 2021 Jul 30.
3
Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
MYD88 L256P 突变的频率及其与成熟 B 细胞肿瘤临床血液学特征的相关性。
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):231-239. doi: 10.1016/j.hemonc.2020.10.003. Epub 2020 Nov 13.
4
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.弥漫性大B细胞淋巴瘤中MYD88和CD79B的致癌突变及其对临床实践的意义。
Cancers (Basel). 2020 Oct 10;12(10):2913. doi: 10.3390/cancers12102913.
5
Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.通过液滴数字 PCR 检测 MYD88 L265P 突变对弥漫性大 B 细胞淋巴瘤的预后价值。
Mol Med Rep. 2020 Aug;22(2):1243-1256. doi: 10.3892/mmr.2020.11186. Epub 2020 May 27.
6
mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.突变可确定弥漫性大 B 细胞淋巴瘤的一个分子亚组,该亚组预后不良。
Haematologica. 2020 Jan 31;105(2):424-434. doi: 10.3324/haematol.2018.214122. Print 2020.
7
Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma.TNFAIP3 的缺失增强了非霍奇金淋巴瘤中 MYD88 驱动的信号转导。
Blood Cancer J. 2018 Oct 9;8(10):97. doi: 10.1038/s41408-018-0130-3.
8
High frequency and prognostic value of L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.弥漫性大B细胞淋巴瘤L265P突变在R-CHOP治疗中的高频性及预后价值
Oncol Lett. 2018 Feb;15(2):1707-1715. doi: 10.3892/ol.2017.7472. Epub 2017 Nov 22.
9
Genetic landscape and deregulated pathways in B-cell lymphoid malignancies.B 细胞淋巴肿瘤的遗传特征和失调信号通路
J Intern Med. 2017 Nov;282(5):371-394. doi: 10.1111/joim.12633. Epub 2017 Jun 20.
10
Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.MYD88 L265P 突变在弥漫性大 B 细胞淋巴瘤中的临床病理意义:一项荟萃分析。
Sci Rep. 2017 May 11;7(1):1785. doi: 10.1038/s41598-017-01998-5.